EUVIMEDEUVIMED entdecken
Open Access

Infant Respiratory Syncytial Virus Immunization Through Maternal Vaccination and Nirsevimab

Karen P Acker, Kevin Strobino, Jessica M DeAngelis, Anna P Staniczenko, Moeun Son, Laura E Riley, Jin-Young Han, Erika L Abramson, Zachary M Grinspan, Deborah A Levine

JAMA Network Open · 2026

DOI: 10.1001/jamanetworkopen.2025.59663 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, 2026. Verfasst von Karen P Acker und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Weill Cornell Medicine, New York, New York. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Vaccines, Vaccination, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance In 2023, 2 forms of respiratory syncytial virus (RSV) prevention, maternal RSV vaccine and nirsevimab, became available for infants. The factors that played a role in their uptake during the first 2 seasons remain unclear.

Objective

To describe the rate of RSV immunization through maternal RSV vaccination or nirsevimab during the 2023-2024 and 2024-2025 RSV seasons and identify the factors associated with their receipt. Design, Setting, and Participants This cohort study was performed at clinical sites affiliated with a quaternary care hospital in New York, New York, from October 1, 2023, to March 31, 2024, and October 1, 2024, to March 31, 2025. Participants included infants younger than 8 months who had at least 1 clinical encounter during the 2023-2024 and 2024-2025 RSV seasons. Main Outcomes and Measures The primary outcomes were receipt of RSV immunization by maternal RSV vaccine 14 days or more prior to delivery or nirsevimab. No evidence of RSV immunization was defined as either no documentation of either product or receipt of maternal vaccine less than 14 days prior to delivery without subsequent nirsevimab immunization. A multinomial logistic regression model was used to estimate odds ratios (ORs) controlling for age, sex, RSV season, insurance, and race and ethnicity, to assess factors associated with vaccination.

Results

Of 13 195 eligible infants (6831 [51.8%] male; 8367 [63.4%] newborn; median age of nonnewborn infants, 17.7 [IQR, 8.1-26.9] weeks), 11 804 of 12 913 (91.4%) were born at term (gestational age ≥37 weeks), 11 208 of 12 964 (86.5%) were privately insured, and 12 109 of 13 195 (91.8%) were born at the study institution. A total of 8830 infants (66.9%) received RSV immunization through maternal RSV vaccine (3832 [29.0%]) or nirsevimab (4998 [37.9%]). RSV immunization coverage increased from 3595 of 6245 infants (57.6%; maternal RSV vaccine, 1317 [21.1%]; nirsevimab, 2278 [36.5%]) in the 2023-2024 season to 5235 of 6950 (75.3%; maternal RSV vaccine, 2515 [36.2%]; nirsevimab, 2720 [39.1%]) in the 2024-2025 season. Increased odds of receiving maternal RSV vaccine (adjusted OR [AOR], 3.58; 95% CI, 3.22-3.99) and nirsevimab (AOR, 1.89; 95% CI, 1.73-2.06) were associated with the 2024-2025 season compared with the 2023-2024 season. Lower odds of receiving maternal RSV vaccine (AOR, 0.18; 95% CI, 0.15-0.22) or nirsevimab (AOR, 0.80; 95% CI, 0.70-0.89) were associated with public compared with private insurance. Conclusions and Relevance In this cohort study of eligible infants younger than 8 months, receipt of RSV immunization through maternal RSV vaccine or nirsevimab improved in the 2024-2025 compared with the 2023-2024 RSV seasons. However, infants with public insurance were less likely to receive either product, highlighting persistent disparities in RSV immunization warranting targeted interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesVaccinationAntibodies, Monoclonal, HumanizedHumansFemaleInfantMaleCohort StudiesNew YorkPregnancyInfant, NewbornAdultRespiratory Syncytial Virus, Human

Substanzen

Respiratory Syncytial Virus VaccinesAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Pediatrics, Weill Cornell Medicine, New York, New York.
  • Department of Medicine, Weill Cornell Medicine, New York, New York.
  • Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, New York.
  • Department of Population Health Sciences, Weill Cornell Medicine, New York, New York.
  • Department of Emergency Medicine, Weill Cornell Medicine, New York, New York.

Zitieren

APA

Acker, K. P., Strobino, K., DeAngelis, J. M., Staniczenko, A. P., Son, M., Riley, L. E., Han, J. Y., Abramson, E. L., Grinspan, Z. M., & Levine, D. A. (2026). Infant Respiratory Syncytial Virus Immunization Through Maternal Vaccination and Nirsevimab. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2025.59663

Vancouver

Acker KP, Strobino K, DeAngelis JM, Staniczenko AP, Son M, Riley LE, et al. Infant Respiratory Syncytial Virus Immunization Through Maternal Vaccination and Nirsevimab. JAMA Network Open. 2026. doi:10.1001/jamanetworkopen.2025.59663

BibTeX
@article{Acker2026,
  author = {Acker, Karen P and Strobino, Kevin and DeAngelis, Jessica M and Staniczenko, Anna P and Son, Moeun and Riley, Laura E and Han, Jin-Young and Abramson, Erika L and Grinspan, Zachary M and Levine, Deborah A},
  title = {Infant Respiratory Syncytial Virus Immunization Through Maternal Vaccination and Nirsevimab},
  journal = {JAMA Network Open},
  year = {2026},
  doi = {10.1001/jamanetworkopen.2025.59663}
}
Kostenlos starten →